Another ADC Secures Over $1 Billion License-Out Deal: Pulzum Discovery Announces Global Partnership for ADCE-T02
Multitude Therapeutics
Innovative Drug Developer
ADCendo
Developer of Novel Anti-Cancer Drugs
On August 20, Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. and ADCendo ApS jointly announced thatA novel, highly differentiated targeted tissue factor (Anti-TF) Antibody-Drug Conjugates (ADC） ——ADCE-T02（Puzhong Discovery Pharmaceutical Technology(Shanghai) Co., Ltd. Development Code AMT-754）Under the licensing agreement, Adcendo will obtain exclusive global development and commercialization rights outside of Greater China, while Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. will retain rights in the Greater China region.Including mainland China, Hong Kong, Macao and Taiwan regions) for development and commercialization rights.
According to the financial terms of the agreement,Puzhong Discovery will receive tens of millions of US dollars as an upfront payment and is entitled to collect total milestone payments exceeding 1 billion US dollars upon achieving subsequent development, regulatory, and commercial milestones., and based on global (Excluding Greater China) A single-digit to low double-digit percentage of net sales as sales royalties.
Tissue Factor (TF) It is overexpressed in bladder cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, esophageal cancer, head and neck cancer, and gastrointestinal cancer, but its expression is limited in normal tissues, making it one of the highly promising ADC targets.
ADCE-T02 is a novel, differentiated ADC targeting TF, utilizing the T1000-exatecan linker-payload platform. Its unique antibody design can reduce the impact on the coagulation pathway. Meanwhile, the T1000-exatecan linker-payload technology platform has been proven by research.Capable of amplifying the "bystander effect," enhancing linker stability, and possessing the potential to overcome drug resistance mechanisms.。
Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. noted in the press release,These differentiated characteristics are expected to translate into higher clinical treatment response rates, longer duration of efficacy, and better safety, offering a more optimal therapeutic window.
Currently, ADCE-T02 has been submitted for clinical trial in Australia and is expected to file for U.S. IND in the near future.
Scan the WeChat QR code to add the editor of Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!
Please indicate: Name + Research Direction!
